Parkin-TLR4-NLRP3 Axis Directs Melatonin to Alleviate Atrazine-Induced Immune Impairment in Splenic Macrophages
- PMID: 39648693
- DOI: 10.1111/jpi.70014
Parkin-TLR4-NLRP3 Axis Directs Melatonin to Alleviate Atrazine-Induced Immune Impairment in Splenic Macrophages
Abstract
Atrazine (ATR) is a widespread environmental herbicide that seriously affects agricultural work and human safety. Melatonin (MLT) as an endogenous neuroendocrine hormone is widely found in animals and plants, which have antioxidant and anti-inflammatory effects. Pink1/Parkin-mediated mitophagy keeps normal physiological processes by degrading damaged mitochondria in cells. Therefore, we investigated the potential role and mechanism of MLT in ATR-induced toxic injury of the spleen. The results showed that MLT alleviated ATR-induced unclear boundary between the white pulp and the red pulp of the spleen. It is also shown that ATR resulted in swollen mitochondria, partial extinction of mitochondrial membranes and cristae, and increased mitophagy under the action of MLT. ATR-induced reactive oxygen species (ROS) activates the Pink1/Parkin pathway, which guides mitophagy development and then causes the activation of TLR4/NF-κB inflammatory pathway. Meanwhile, these damages further exacerbated the production of NLRP3 inflammasomes, leading to spleen necrosis. Interestingly, these changes were improved after MLT treatment. Collectively, we found that MLT alleviates ATR-induced immune impairment in splenic macrophages via regulating Parkin-TLR4-NLRP3 axis which elucidates the effect of melatonin on the spleen and provides a novel perspective on melatonin in splenic inflammatory injury treatment.
Keywords: Atrazine; Parkin; melatonin; mitophagy; spleen injury.
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
References
-
- C. Venegas, J. A. García, G. Escames, et al., “Extrapineal Melatonin: Analysis of Its Subcellular Distribution and Daily Fluctuations,” Journal of Pineal Research 52, no. 2 (2012): 217–227.
-
- Y. Zhang, T. Liu, H. Yang, F. He, and X. Zhu, “Melatonin: A Novel Candidate for the Treatment of Osteoarthritis,” Ageing Research Reviews 78 (2022): 101635.
-
- J. V. Gandolfi, A. P. A. Di Bernardo, D. A. V. Chanes, et al., “The Effects of Melatonin Supplementation on Sleep Quality and Assessment of the Serum Melatonin in ICU Patients: A Randomized Controlled Trial,” Critical Care Medicine 48, no. 12 (2020): e1286–e1293.
-
- R. Hardeland, “Aging, Melatonin, and the Pro‐ and Anti‐Inflammatory Networks,” International Journal of Molecular Sciences 20, no. 5 (2019): 1223.
-
- A. Carrillo‐Vico, P. Lardone, N. Álvarez‐Sánchez, A. Rodríguez‐Rodríguez, and J. Guerrero, “Melatonin: Buffering the Immune System,” International Journal of Molecular Sciences 14, no. 4 (2013): 8638–8683.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous